Mood stabilizers (lithium, valproic acid, lamotrigine) reduce mood episode frequency and severity in bipolar disorder through various mechanisms. Lithium remains the gold standard with the most evidence for suicide prevention. Mood stabilizers require careful monitoring for therapeutic levels and side effects.
You know from your bipolar I training that the disorder involves recurring manic and depressive episodes, often with a cyclical course. The therapeutic challenge is unusual: the same drug must prevent both mood poles simultaneously, or at least reduce their frequency and severity over time. This is categorically different from treating unipolar depression, where you simply want to raise mood. A medication that lifts mood too aggressively in a bipolar patient can precipitate mania; one that blunts mania too hard may deepen depression. Mood stabilizers solve this problem by operating on the cycling mechanism itself rather than targeting a specific pole.
Lithium has been the gold standard since the 1950s — one of psychiatry's oldest and most empirically validated treatments. Its mechanisms are still not fully understood, but two leading candidates are inhibition of inositol monophosphatase (disrupting second-messenger signaling that amplifies neural excitability) and inhibition of glycogen synthase kinase-3β (GSK-3β), a kinase involved in cellular excitability and neuroplasticity. Lithium's remarkable clinical distinction is its anti-suicide effect, which is robust across multiple studies and appears independent of its antimanic action — possibly because it reduces impulsivity and aggression. The cost of this efficacy is a narrow therapeutic window: the difference between a therapeutic level (0.6–1.2 mEq/L serum) and a toxic level is small. Toxicity manifests as tremor, confusion, ataxia, and in severe cases cardiac arrhythmia and seizures. Regular serum monitoring and thyroid/renal function tests are mandatory because lithium is renally cleared and can impair thyroid function with long-term use.
Valproic acid (valproate) has broader indications, including acute mania where rapid onset matters. Its mechanisms include enhancement of GABA transmission, sodium channel blockade, and histone deacetylase inhibition (an epigenetic effect). Valproate is often preferred over lithium for mixed episodes and rapid cycling. Lamotrigine works differently: it blocks voltage-gated sodium channels and inhibits glutamate release, and its clinical profile is almost the inverse of valproate — it is more effective at preventing depressive episodes than manic ones, making it particularly valuable for bipolar II or maintenance after a depressive episode. The clinical art is matching agent to patient profile: lithium for classic euphoric mania with suicidality, valproate for mixed/dysphoric mania, lamotrigine for depression-predominant courses. All three require slow titration and sustained monitoring — these are not "start and forget" medications, but ongoing therapeutic partnerships with careful surveillance.